cefotaxime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 546 63527-52-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefotaxime
  • cefotaxime sodium
  • cephotaxime
  • cefotaxime sodium salt
Semisynthetic broad-spectrum cephalosporin.
  • Molecular weight: 455.46
  • Formula: C16H17N5O7S2
  • CLOGP: 0.33
  • LIPINSKI: 1
  • HAC: 12
  • HDO: 3
  • TPSA: 173.51
  • ALOGS: -3.49
  • ROTB: 8
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
4 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 30 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 376.38 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.19 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.70 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.60 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.20 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 50 mg/mL Bocci G, Oprea TI, Benet LZ
BA (Bioavailability) 0 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.606 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 2.992 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.482 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 3.864 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 65.480 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 40.170 % High 1
herg hERG pIC50 4.147 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 5.768 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 10.568 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 27.360 % High 1
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,DYRK3,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MELK,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PIM3,PRKAA1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2 74
kinase-selectivity-class AXL,BRAF,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,JAK2,MAP2K6,MAP3K14,MAPK12,MAPK7,PIM3,PRKDC,STK33,SYK,TEK,TGFBR1,TTK 21
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 2.710 High 0.89
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.762 High 1
mh-clint Mouse hepatocyte intrinsic clearance 35.563 High 1
mppb Mouse plasma protein binding (% unbound) 50.460 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.603 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 32.420 % High 1
rat-kpuu-brain Rat brain Kpuu 0.010 % High 0.89
rh-clint Rat hepatocyte intrinsic clearance 12.190 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 90.520 % High 1
rppb Rat plasma protein binding (% unbound) 24.660 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 895.365 uM High 1

Approvals:

DateAgencyCompanyOrphan
March 11, 1981 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 366.47 28.86 133 6686 42625 90579003
Toxic epidermal necrolysis 205.35 28.86 81 6738 32447 90589181
Hepatocellular injury 175.40 28.86 70 6749 28888 90592740
Eosinophilia 132.27 28.86 57 6762 28476 90593152
Rash maculo-papular 124.47 28.86 61 6758 40872 90580756
Stevens-Johnson syndrome 105.21 28.86 49 6770 29327 90592301
Acute generalised exanthematous pustulosis 93.03 28.86 36 6783 13667 90607961
Septic shock 92.95 28.86 65 6754 84095 90537533
Pyrexia 87.37 28.86 168 6651 660317 89961311
Premature baby 87.23 28.86 41 6778 25036 90596592
Acute kidney injury 80.11 28.86 109 6710 320278 90301350
Multiple organ dysfunction syndrome 73.62 28.86 52 6767 68284 90553344
Agranulocytosis 71.56 28.86 40 6779 34962 90586666
Dysbiosis 71.17 28.86 18 6801 1684 90619944
Patent ductus arteriosus 69.87 28.86 22 6797 4547 90617081
Cholestasis 67.52 28.86 39 6780 36260 90585368
Hepatic cytolysis 65.02 28.86 36 6783 30880 90590748
Purpura 60.28 28.86 27 6792 14751 90606877
Generalised tonic-clonic seizure 50.70 28.86 32 6787 34871 90586757
Clostridium difficile colitis 50.48 28.86 29 6790 26677 90594951
Laryngeal stenosis 50.29 28.86 13 6806 1326 90620302
Haemophagocytic lymphohistiocytosis 49.85 28.86 24 6795 15435 90606193
Umbilical erythema 49.55 28.86 8 6811 72 90621556
Foetal exposure during pregnancy 49.30 28.86 34 6785 42941 90578687
Hydrocephalus 48.54 28.86 18 6801 6076 90615552
Fatigue 47.67 28.86 14 6805 1154009 89467619
Sepsis 47.62 28.86 63 6756 179751 90441877
Cross sensitivity reaction 44.70 28.86 14 6805 2843 90618785
Encephalopathy 44.65 28.86 33 6786 46411 90575217
Necrosis 43.56 28.86 17 6802 6593 90615035
Hyperbilirubinaemia 40.04 28.86 20 6799 13916 90607712
Neutropenia 39.57 28.86 65 6754 224839 90396789
Arthralgia 39.11 28.86 6 6813 778516 89843112
Thrombocytopenia 39.00 28.86 62 6757 208663 90412965
Subperiosteal abscess 37.70 28.86 5 6814 8 90621620
Epidermolysis 37.21 28.86 9 6810 700 90620928
Disseminated intravascular coagulation 37.03 28.86 22 6797 21516 90600112
Dermatitis bullous 36.27 28.86 17 6802 10299 90611329
Necrotising enterocolitis neonatal 34.57 28.86 7 6812 239 90621389
Lactic acidosis 33.80 28.86 29 6790 50434 90571194
Pancreatitis acute 33.55 28.86 24 6795 32091 90589537
Ventricular dysfunction 33.35 28.86 12 6807 3719 90617909
Pseudomembranous colitis 32.93 28.86 12 6807 3856 90617772
Petechiae 32.19 28.86 18 6801 15723 90605905
Central nervous system necrosis 30.85 28.86 6 6813 166 90621462
Pulmonary necrosis 30.51 28.86 6 6813 176 90621452
Pneumonia bacterial 29.96 28.86 16 6803 12774 90608854
Stenotrophomonas infection 29.82 28.86 10 6809 2519 90619109
Toxic skin eruption 29.46 28.86 17 6802 15757 90605871
Hepatic failure 29.02 28.86 24 6795 39704 90581924
Oligohydramnios 28.86 28.86 13 6806 7188 90614440

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 382.18 23.01 175 7577 41900 42571683
Rash maculo-papular 211.79 23.01 113 7639 37390 42576193
Hepatocellular injury 188.35 23.01 90 7662 23588 42589995
Toxic epidermal necrolysis 129.87 23.01 73 7679 26677 42586906
Eosinophilia 108.41 23.01 70 7682 32829 42580754
Clostridium difficile colitis 95.08 23.01 55 7697 21197 42592386
Agranulocytosis 90.79 23.01 61 7691 30551 42583032
Acute generalised exanthematous pustulosis 81.72 23.01 37 7715 8558 42605025
Hepatic cytolysis 71.33 23.01 50 7702 26794 42586789
Toxic skin eruption 70.77 23.01 39 7713 13691 42599892
Acute kidney injury 70.11 23.01 184 7568 367153 42246430
Cholestasis 68.76 23.01 53 7699 32826 42580757
Haemophagocytic lymphohistiocytosis 65.54 23.01 41 7711 18181 42595402
Serratia sepsis 60.30 23.01 12 7740 148 42613435
Pyrexia 55.42 23.01 177 7575 393865 42219718
Purpura 53.79 23.01 31 7721 11848 42601735
Urethral valves 48.96 23.01 11 7741 250 42613333
Serratia infection 47.86 23.01 15 7737 1254 42612329
Thrombocytopenia 45.35 23.01 104 7648 190175 42423408
Bicytopenia 41.05 23.01 17 7735 3167 42610416
Neutropenia 40.01 23.01 102 7650 199329 42414254
Fatigue 39.54 23.01 15 7737 435626 42177957
Vasculitis necrotising 38.61 23.01 12 7740 976 42612607
Klebsiella infection 37.01 23.01 24 7728 11308 42602275
Red blood cell schistocytes present 35.63 23.01 9 7743 341 42613242
Dermatitis bullous 35.46 23.01 21 7731 8435 42605148
Thrombotic microangiopathy 33.47 23.01 25 7727 14757 42598826
Mixed liver injury 32.49 23.01 16 7736 4458 42609125
Drug ineffective 28.75 23.01 204 7548 629993 41983590
Pancytopenia 28.71 23.01 65 7687 117678 42495905
Nausea 28.00 23.01 19 7733 396780 42216803
Respiratory gas exchange disorder 27.59 23.01 8 7744 513 42613070
Death 26.59 23.01 28 7724 471157 42142426
Encephalopathy 26.40 23.01 35 7717 41298 42572285
Gamma-glutamyltransferase increased 26.33 23.01 31 7721 32466 42581117
Face oedema 26.32 23.01 21 7731 13645 42599938
ADAMTS13 activity decreased 26.31 23.01 6 7746 146 42613437
Hyperbilirubinaemia 26.19 23.01 25 7727 20610 42592973
Haematoma muscle 26.10 23.01 11 7741 2139 42611444
CD4 lymphocytes increased 25.89 23.01 6 7746 157 42613426
Pseudomembranous colitis 25.15 23.01 12 7740 3121 42610462
Septic shock 25.05 23.01 53 7699 91619 42521964
Systemic candida 24.39 23.01 14 7738 5305 42608278
Abscess 23.48 23.01 20 7732 14228 42599355
Drug resistance 23.43 23.01 30 7722 34218 42579365
Rash erythematous 23.36 23.01 29 7723 32062 42581521

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 758.28 24.69 303 12526 81792 110494678
Rash maculo-papular 349.71 24.69 171 12658 74051 110502419
Hepatocellular injury 329.73 24.69 146 12683 50496 110525974
Toxic epidermal necrolysis 304.56 24.69 143 12686 56584 110519886
Eosinophilia 250.59 24.69 126 12703 57810 110518660
Agranulocytosis 168.47 24.69 99 12730 61661 110514809
Acute kidney injury 150.53 24.69 266 12563 635164 109941306
Acute generalised exanthematous pustulosis 149.10 24.69 65 12764 21599 110554871
Clostridium difficile colitis 145.86 24.69 80 12749 43698 110532772
Hepatic cytolysis 139.06 24.69 84 12745 54969 110521501
Pyrexia 133.85 24.69 310 12519 897955 109678515
Cholestasis 124.41 24.69 83 12746 64435 110512035
Purpura 117.12 24.69 57 12772 24331 110552139
Toxic skin eruption 104.87 24.69 55 12774 27460 110549010
Stevens-Johnson syndrome 99.33 24.69 64 12765 46837 110529633
Haemophagocytic lymphohistiocytosis 89.73 24.69 52 12777 31507 110544963
Septic shock 88.50 24.69 100 12729 157428 110419042
Thrombocytopenia 87.44 24.69 150 12679 348735 110227735
Fatigue 76.89 24.69 23 12806 1215935 109360535
Neutropenia 72.37 24.69 144 12685 374476 110201994
Dermatitis bullous 69.53 24.69 36 12793 17493 110558977
Encephalopathy 64.45 24.69 62 12767 80993 110495477
Pain 64.17 24.69 16 12813 954939 109621531
Mixed liver injury 60.30 24.69 29 12800 12050 110564420
Pseudomembranous colitis 60.22 24.69 24 12805 6367 110570103
Serratia sepsis 59.03 24.69 12 12817 267 110576203
Multiple organ dysfunction syndrome 58.89 24.69 80 12749 151630 110424840
Cross sensitivity reaction 56.29 24.69 22 12807 5545 110570925
Nausea 54.01 24.69 39 12790 1235651 109340819
Arthralgia 50.55 24.69 14 12815 779618 109796852
Hyperbilirubinaemia 48.61 24.69 35 12794 30636 110545834
Red blood cell schistocytes present 46.88 24.69 12 12817 759 110575711
Serratia infection 45.98 24.69 15 12814 2244 110574226
Bicytopenia 45.68 24.69 20 12809 6704 110569766
Thrombotic microangiopathy 45.60 24.69 33 12796 29116 110547354
Laryngeal stenosis 44.16 24.69 13 12816 1385 110575085
Rash morbilliform 39.42 24.69 19 12810 7932 110568538
Vasculitis necrotising 38.35 24.69 12 12817 1571 110574899
Epidermolysis 37.41 24.69 11 12818 1167 110575303
Anaphylactic shock 36.45 24.69 37 12792 51509 110524961
Nasopharyngitis 34.65 24.69 3 12826 394358 110182112
Hydrocephalus 34.64 24.69 19 12810 10356 110566114
Generalised tonic-clonic seizure 32.88 24.69 36 12793 54644 110521826
Hepatic failure 32.52 24.69 40 12789 68699 110507771
Klebsiella infection 32.09 24.69 23 12806 19986 110556484
Drug resistance 31.98 24.69 36 12793 56338 110520132
Cholestatic liver injury 31.72 24.69 16 12813 7360 110569110
Pancytopenia 31.66 24.69 73 12756 209540 110366930
Face oedema 31.23 24.69 28 12801 33441 110543029
Pain in extremity 31.06 24.69 9 12820 487109 110089361
Weight increased 30.19 24.69 6 12823 419638 110156832
Abdominal discomfort 29.69 24.69 5 12824 393853 110182617
Rash macular 29.62 24.69 29 12800 38657 110537813
Enterococcal infection 29.47 24.69 22 12807 20344 110556126
Erythema 29.15 24.69 87 12742 291360 110285110
Peripheral swelling 28.60 24.69 6 12823 404028 110172442
Sepsis 28.39 24.69 93 12736 327253 110249217
Drug ineffective 28.11 24.69 284 12545 1520256 109056214
Haemolytic uraemic syndrome 28.05 24.69 13 12816 4972 110571498
Rash erythematous 27.06 24.69 40 12789 81792 110494678
Respiratory gas exchange disorder 26.84 24.69 8 12821 890 110575580
Haemolytic anaemia 26.76 24.69 21 12808 20899 110555571
Depression 26.34 24.69 3 12826 317332 110259138
Insomnia 26.26 24.69 5 12824 360585 110215885
Subperiosteal abscess 26.15 24.69 5 12824 80 110576390
Ventricular dysfunction 25.75 24.69 14 12815 7497 110568973
Transaminases increased 25.44 24.69 34 12795 63356 110513114
Pancreatitis acute 25.23 24.69 33 12796 60241 110516229
Brain oedema 25.10 24.69 24 12805 31074 110545396
Gamma-glutamyltransferase increased 24.78 24.69 33 12796 61276 110515194
CNS ventriculitis 24.74 24.69 7 12822 648 110575822

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute generalised exanthematous pustulosis 33.32 29.42 8 190 19 113736

Pharmacologic Action:

SourceCodeDescription
ATC J01DD01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
ATC J01DD51 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:35441 antiinfective agent
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:88188 drug allergen

Related Drugs by ATC class:

J01DD Third-generation cephalosporins 17 drugs
cefcapenecefdinircefditoren pivoxilcefetametcefiximecefmenoximecefodizimecefoperazonecefpiramidecefpodoxime proxetilcefsulodinceftazidime show all 17 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Streptococcal meningitis indication 4510004 DOID:11574
Septicemia due to Escherichia coli indication 9323009
Bacterial septicemia indication 10001005 DOID:0040085
Infection of skin AND/OR subcutaneous tissue indication 19824006
Staphylococcal pneumonia indication 22754005
Streptococcal septicemia indication 29577008
Pneumonia due to Streptococcus indication 34020007
Neonatal conjunctivitis indication 34298002 DOID:9699
Pneumonia due to Pseudomonas indication 41381004
Bacterial arthritis indication 48245008
Peritonitis indication 48661000
Lower respiratory tract infection indication 50417007
Pneumonia due to Escherichia coli indication 51530003
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Haemophilus influenzae pneumonia indication 70036007
Bacterial infection due to Serratia indication 71120004
Septicemia due to Serratia indication 82091000
Bacterial meningitis indication 95883001 DOID:9470
Infection of bone indication 111253001
Female genital tract infection indication 125585007
Infectious disease of abdomen indication 128070006
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Meningococcal meningitis indication 192644005
Escherichia coli meningitis indication 192655005
Proteus pneumonia indication 195888009
Sepsis of the newborn indication 206376005
Neonatal pneumonia indication 233619008
Neonatal meningitis indication 276674008
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Bacterial urinary infection indication 312124009
Meningitis due to Klebsiella mobilis indication 420585007
Sepsis due to Staphylococcus aureus indication 448417001
Cesarean Section Infection Prevention indication
Streptococcal Peritonitis indication
E. Coli Peritonitis indication
E. Coli Endometritis indication
Haemophilus Influenzae Type B Infections indication
Neonatal Group B Streptococcal Septicemia indication
Klebsiella Endometritis indication
Proteus Endometritis indication
Enterococcus Pelvic Cellulitis indication
Prevention of Perioperative Infection indication
Proteus Mirabilis Osteomyelitis indication
Bacteroides Pelvic Cellulitis indication
Klebsiella Pelvic Inflammatory Disease indication
Staphylococcus Endometritis indication
H. Influenzae Meningitis indication
Clostridium Pelvic Inflammatory Disease indication
Haemophilus Parainfluenzae Pneumonia indication
Bacteroides Pelvic Inflammatory Disease indication
Staphylococcus Pelvic Inflammatory Disease indication
Proteus Peritonitis indication
Clostridium Endometritis indication
Staphylococcus Epidermidis Urinary Tract Infection indication
Enterococcus Pelvic Inflammatory Disease indication
Morganella Morganii Urinary Tract Infection indication
Fusobacterium Pelvic Inflammatory Disease indication
Streptococcus Osteomyelitis indication
Enterococcus Urinary Tract Infection indication
Clostridium Pelvic Cellulitis indication
Serratia Urinary Tract Infection indication
Enterobacter Pneumonia indication
Enterobacter Pelvic Inflammatory Disease indication
Bacteroides Endometritis indication
Providencia Urinary Tract Infection indication
Citrobacter Urinary Tract Infection indication
Fusobacterium Endometritis indication
Proteus Pelvic Inflammatory Disease indication
Clostridium Peritonitis indication
Staphylococcus Aureus Urinary Tract Infection indication
E. Coli Pelvic Inflammatory Disease indication
E. Coli Pelvic Cellulitis indication
Enterobacter Endometritis indication
Pseudomonas Aeruginosa Urinary Tract Infection indication
Klebsiella Pneumoniae Peritonitis indication
Enterococcus Endometritis indication
Pyrexia of unknown origin off-label use 7520000
Acute gonococcal cervicitis off-label use 20943002 DOID:10615
Lyme disease off-label use 23502006 DOID:11729
Acute gonococcal urethritis off-label use 29864006
Lyme arthritis off-label use 33937009
Pseudotuberculosis off-label use 36753006
Gonorrhea of rectum off-label use 42746002
Lyme carditis off-label use 77863005
Infection by Yersinia enterocolitica off-label use 80960004
Ventilator-acquired pneumonia off-label use 429271009
Disseminated Gonococcal Infection off-label use
Lyme Disease of the Central Nervous System off-label use
Acute nephropathy contraindication 58574008
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.39 acidic
pKa2 13.31 acidic
pKa3 3.1 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Peptidoglycan synthase FtsI Enzyme INHIBITOR IC50 6.24 WOMBAT-PK CHEMBL
Penicillin-binding protein 1A Enzyme INHIBITOR IC50 6.51 WOMBAT-PK CHEMBL
Penicillin-binding protein 1B Enzyme INHIBITOR IC50 5.66 WOMBAT-PK CHEMBL
Penicillin-binding protein 2 Enzyme INHIBITOR IC50 4.62 WOMBAT-PK CHEMBL
Beta-lactamase Enzyme Ki 6.30 CHEMBL
Beta-lactamase Enzyme Ki 5.60 CHEMBL

External reference:

IDSource
4019663 VUID
N0000147755 NUI
D00919 KEGG_DRUG
64485-93-4 SECONDARY_CAS_RN
203117 RXNORM
C0007554 UMLSCUI
CHEBI:3498 CHEBI
CE3 PDB_CHEM_ID
CHEMBL1730 ChEMBL_ID
CHEMBL1010 ChEMBL_ID
D002439 MESH_DESCRIPTOR_UI
DB00493 DRUGBANK_ID
10893 IUPHAR_LIGAND_ID
4504 INN_ID
N2GI8B1GK7 UNII
5742673 PUBCHEM_CID
42787 MMSL
4378 MMSL
d00008 MMSL
3334000 SNOMEDCT_US
372704003 SNOMEDCT_US
41722006 SNOMEDCT_US
4018466 VANDF
4019663 VANDF
002727 NDDF
004845 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cefotaxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9930 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 24 sections
Cefotaxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9931 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 24 sections
Cefotaxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9933 INJECTION, POWDER, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 24 sections
Cefotaxime HUMAN PRESCRIPTION DRUG LABEL 1 0143-9935 INJECTION 10 g INTRAVENOUS ANDA 24 sections
Cefotaxime HUMAN PRESCRIPTION DRUG LABEL 1 21586-011 POWDER, FOR SOLUTION 1 g INTRAMUSCULAR Unapproved drug for use in drug shortage 2 sections
Cefotaxime HUMAN PRESCRIPTION DRUG LABEL 1 21586-012 POWDER, FOR SOLUTION 2 g INTRAMUSCULAR Unapproved drug for use in drug shortage 2 sections
CEFOTAXIME HUMAN PRESCRIPTION DRUG LABEL 1 55648-947 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 11 sections
CEFOTAXIME HUMAN PRESCRIPTION DRUG LABEL 1 55648-948 INJECTION, POWDER, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 11 sections
CEFOTAXIME HUMAN PRESCRIPTION DRUG LABEL 1 55648-986 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 11 sections
Cefotaxime HUMAN PRESCRIPTION DRUG LABEL 1 64679-947 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 20 sections
Cefotaxime HUMAN PRESCRIPTION DRUG LABEL 1 64679-948 INJECTION, POWDER, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 20 sections
Cefotaxime HUMAN PRESCRIPTION DRUG LABEL 1 64679-986 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 20 sections